Brendan Teehan named Chief Commercial Officer and Krys Corbett named Chief Business Officer -- -- Key additions expected to ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

Eight of the 30 Dow components lost value in 2024. Here's a quick look at each company, to help you determine which dividend ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

There are currently no treatments available for celiac disease beyond a gluten-free diet. Several late-phase companies aim to ...

Rory McIlroy was all set for his second Irish Open triumph going into the final day but he was overtaken by a great Dane at ...

Rory McIlroy has confirmed his Irish Open ambitions for 2025 after reflecting on last year’s ‘unforgettable’ Royal County Down experience.

Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

A study published in Nature Medicine looks at the health risks and benefits linked to GLP-1 receptor agonists. Prof Naveed Sattar, Professor of Cardiometabolic Medicine/Honorary Consultant, University ...